Skip to content
buyNotable cluster of 4

Joao Siffert MD bought $63k of DSGN

President and CEO at Design Therapeutics, Inc.. 7,450 shares at an average of $8.39, traded Dec 19, 2022, filed Dec 21, 2022.

Conviction score
69
Value
$63k
7,450 shares
Holdings after
132,619
+6% from before
From 52-week low
+6%
low $7.86, close $8.33
From 52-week high
-67%
high $25.57, as of Dec 19, 2022

Score components

  • Role
    CEO
    +25
  • Trade size
    $63k at market
    +8
  • Relative to holdings
    Holdings up 6%
    +3
  • Price context
    6% above the 52-week low; 67% below the 52-week high
    +18
  • Cluster
    4 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

DSGNOct 12, 2026 · close 10.91
Since filing Dec 21, 2022: +28.5%SPY +111.2% · excess -82.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001209191-22-062349, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 19, 2022POpen-market purchase
Common Stock
+1,150$8.47$9,741126,319Dec 21, 2022
Dec 20, 2022POpen-market purchase
Common Stock
+6,300$8.38$53k132,619Dec 21, 2022

Related signals

Other insiders at Design Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
45Moderate
DSGNsell
Design Therapeutics, Inc.
Arsani William
director
$3.0M
562,627 shares
-19%
20Weak
DSGNsell
Design Therapeutics, Inc.
Deepa Prasad
director
$24k
3,806 shares
-16%
60Notable
DSGNsell
Design Therapeutics, Inc.
Arsani William
director
$3.5M
814,874 shares
-100%
39Weak
DSGNbuy 2
Design Therapeutics, Inc.
Heather A. Berger
director
$4,866
1,300 shares
-
49Moderate
DSGNbuy 2
Design Therapeutics, Inc.
John P. Schmid
director
$100k
26,965 shares
-
58Moderate
DSGNbuy 4
Design Therapeutics, Inc.
SR One Capital Fund I Aggregator LP
owner
$7.6M
900,000 shares
+16%
66Notable
DSGNbuy 4
Design Therapeutics, Inc.
Simeon George
director, owner
$7.6M
900,000 shares
+16%
61Notable
DSGNbuy 4
Design Therapeutics, Inc.
Rodney W Lappe
director
$119k
15,000 shares
+15%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Joao Siffert MD bought $63k of DSGN | InsiderTell